Life Sciences Partners

About The Fund

Life Sciences Partners (LSP), now part of EQT Life Sciences, is a leading venture capital firm investing in the life sciences sector. With headquarters in Amsterdam, Netherlands, they concentrate on financing innovative companies across BioTech, HealthTech, Medical Devices, Healthcare, and Life Sciences globally. They specialize in providing equity and debt financing to startups, early-stage companies, and businesses in expansion phases. The fund has a significant asset under management of 2 billion euros and invests in ventures with a minimum of 500,000 euros to a maximum of 10 million euros. Over a 30-year history, EQT Life Sciences has raised around 3.5 billion euros across 12 private funds, applying three main investment strategies: Life Sciences Funds (focused on drug development at all stages), Health Economic Funds (targeting later-stage MedTech, Digital Health, and Diagnostics to enhance care quality and curtail healthcare costs), and the Dementia Fund (supporting drug development and medical technology for neurodegenerative diseases). The firm is driven by demographic trends, unmet medical needs, record levels of innovation, and robust market momentum, evidenced by high M&A activity within the sector. They aim to transform scientific innovation into impactful healthcare solutions that improve patient quality of life by addressing clinical needs. By partnering with the inventors, they contribute strategic, clinical, operational, financial, and commercial guidance and support. Their portfolio includes companies like Amolyt Pharma, Neuravi, New Amsterdam Pharma, Onera Health, and PanTera, which reflect their commitment to fostering innovations that address rare diseases, advance stroke therapy, provide novel lipid-lowering therapies, reimagine sleep diagnosis, and enhance cancer treatments with radioisotopes.